Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Verici Dx Plc ( (GB:VRCI) ).
Verici Dx Plc has reported significant progress in the commercial adoption of its Tutivia™ test, with a 19% increase in ordering clinicians and the onboarding of nine new transplant centers in Q3, now covering 16% of annual transplants in the US. The company has strengthened its commercial team with new hires, anticipating volume growth from Q4, and remains on track to meet market expectations for the year.
The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.
Spark’s Take on GB:VRCI Stock
According to Spark, TipRanks’ AI Analyst, GB:VRCI is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including ongoing losses and negative cash flows. Technical analysis provides some short-term positive signals, but valuation remains unattractive due to negative earnings. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on GB:VRCI stock, click here.
More about Verici Dx Plc
Verici Dx Plc is a company specializing in advanced clinical diagnostics for organ transplants. Their primary product, the Tutivia™ test, is designed to detect acute rejection in post-transplant patients. The company focuses on expanding its market presence in the United States, aiming to enhance the adoption of its diagnostic solutions across transplant centers.
Average Trading Volume: 2,953,868
Technical Sentiment Signal: Sell
Current Market Cap: £9.84M
For detailed information about VRCI stock, go to TipRanks’ Stock Analysis page.